Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 22:14:60.
doi: 10.1186/s12986-017-0217-z. eCollection 2017.

Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis

Xiangyun Zhu  1 , Chunhua Wu  1 , Shanhu Qiu  1 , Xuelu Yuan  1 , Ling Li  1
Affiliations
Review

Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis

Xiangyun Zhu et al. Nutr Metab (Lond). .

Abstract

Although the regular consumption of resveratrol has been known to improve glucose homeostasis and reverse insulin resistance in type 2 diabetes mellitus (T2DM), the reported results are inconsistent. Thus, we aimed to assess the effects of resveratrol on glycemic control and insulin sensitivity among patients with T2DM. We searched for relevant articles published until June 2017 on PubMed-Medline, Embase, Cochrane Library, and Web of Science. Randomized controlled trials in T2DM patients administered with resveratrol as intervention were included. After study selection, quality assessment and data extraction were performed independently by two authors, and STATA and RevMan software were used for statistical analysis. Nine randomized controlled trials involving 283 participants were included. Meta-analysis showed that resveratrol significantly improved the fasting plasma glucose ( -0.29 mmol/l, 95% CI: -0.51, -0.06, p < 0.01) and insulin levels (-0.64 U/mL, 95% CI: -0.95, -0.32, p < 0.0001). The drug also reduced homeostasis model assessment of insulin resistance (HOMA-IR) index, systolic blood pressure, and diastolic blood pressure among participants with T2DM. The changes in hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were negligible. Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose. In particular, the latter dose presented more favorable results. This meta-analysis provides evidence that supplementation of resveratrol may benefit management of T2DM.

Keywords: Meta-analysis; Resveratrol; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Each author meets the criteria for authorship and assumes the corresponding responsibility.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow diagram of the study selection procedure showing the number of eligible articles included in the meta-analysis
Fig. 2
Fig. 2
Forest plot of effect of resveratrol on fasting plasma glucose
Fig. 3
Fig. 3
Forest plot of effect of resveratrol on HbA1c
Fig. 4
Fig. 4
Forest plot of effect of resveratrol on homeostatic model assessment of insulin resistance
See this image and copyright information in PMC

References

    1. Jeffery N, Harries LW. Beta-cell differentiation status in type 2 diabetes. Diabetes, obesity & metabolism. 2016;18:1167–1175. doi: 10.1111/dom.12778. - DOI - PubMed
    1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–149. doi: 10.1016/j.diabres.2013.11.002. - DOI - PubMed
    1. Martin CL, Albers JW, Pop-Busui R, Group DER Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:31–38. doi: 10.2337/dc13-2114. - DOI - PMC - PubMed
    1. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:293–301. doi: 10.1016/j.diabres.2010.01.026. - DOI - PubMed
    1. Bain SC, Feher M, Russell-Jones D, Khunti K. Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. Diabetes Obes Metab. 2016;18:1157–1166. doi: 10.1111/dom.12760. - DOI - PubMed

LinkOut - more resources